Michelle Lavin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8616979/publications.pdf

Version: 2024-02-01

48 papers	1,021 citations	516561 16 h-index	454834 30 g-index
49 all docs	49 docs citations	49 times ranked	1086 citing authors

#	Article	IF	Citations
1	Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance. Blood Advances, 2023, 7, 302-308.	2.5	3
2	Examining international practices in the management of pregnant women with von Willebrand disease. Journal of Thrombosis and Haemostasis, 2022, 20, 82-91.	1.9	7
3	Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. Blood Advances, 2022, 6, 228-237.	2.5	15
4	Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study. European Journal of Haematology, 2022, 108, 518-527.	1.1	7
5	Transfusion requirements in patients with COVIDâ€19. European Journal of Haematology, 2021, 106, 132-134.	1.1	5
6	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. Journal of Thrombosis and Haemostasis, 2021, 19, 701-710.	1.9	7
7	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 2021, 5, 301-325.	2.5	152
8	Harnessing Twitter to empower scientific engagement and communication: The ISTH 2020 virtual congress experience. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 253-260.	1.0	8
9	Current Challenges in the Peripartum Management of Women with von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 2021, 47, 217-228.	1.5	12
10	A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. Haemophilia, 2021, 27, 544-562.	1.0	12
11	Vaccineâ€induced immune thrombotic thrombocytopenia (VITT) â€“ a novel clinicoâ€pathological entity with heterogeneous clinical presentations. British Journal of Haematology, 2021, 195, 76-84.	1.2	42
12	ADAMTS13 regulation of VWF multimer distribution in severe COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 1914-1921.	1.9	58
13	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	1.0	2
14	Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. Journal of Clinical Medicine, 2021, 10, 3536.	1.0	5
15	European principles of care for women and girls with inherited bleeding disorders. Haemophilia, 2021, 27, 837-847.	1.0	23
16	Online Search Trends Influencing Anticoagulation in Patients With COVID-19: Observational Study. JMIR Formative Research, 2021, 5, e21817.	0.7	0
17	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVIDâ€19): evidence of acute and sustained endothelial cell activation. British Journal of Haematology, 2021, 192, 714-719.	1.2	92
18	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	2.5	5

#	Article	IF	Citations
19	Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices. Thrombosis Update, 2021, 5, 100086.	0.4	4
20	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	1.0	32
21	Clinical management of woman with bleeding disorders: A survey among European haemophilia treatment centres. Haemophilia, 2020, 26, 657-662.	1.0	12
22	The impact of foetal restrictions on mode of delivery in women with inherited bleeding disorders. European Journal of Haematology, 2020, 105, 555-560.	1.1	1
23	Standardizing care to manage bleeding disorders in adolescents with heavy mensesâ€"A joint project from the ISTH pediatric/neonatal and women's health SSCs. Journal of Thrombosis and Haemostasis, 2020, 18, 2759-2774.	1.9	11
24	Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations. Blood, 2020, 136, 29-29.	0.6	0
25	Barriers and challenges faced by women with congenital bleeding disorders in Europe: Results of a patient survey conducted by the European Haemophilia Consortium. Haemophilia, 2019, 25, 468-474.	1.0	38
26	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	0.6	32
27	Perioperative management of patients with von Willebrand disease. Hematology American Society of Hematology Education Program, 2019, 2019, 604-609.	0.9	14
28	How I treat low von Willebrand factor levels. Blood, 2019, 133, 795-804.	0.6	36
29	Missed at first Glanz: Glanzmann thrombasthenia initially misdiagnosed as Von Willebrand Disease. Transfusion and Apheresis Science, 2019, 58, 58-60.	0.5	5
30	Management of combined factor V and factor VIII deficiency in pregnancy. Journal of Obstetrics and Gynaecology, 2019, 39, 271-272.	0.4	4
31	Preparing for menarche: treatment and management of heavy periods in women with bleeding disorders. The Journal of Haemophilia Practice, 2019, 6, 24-27.	0.2	0
32	Bleeding disorders in girls and women: setting the scene. The Journal of Haemophilia Practice, 2019, 6, 3-9.	0.2	1
33	A role for intravenous immunoglobulin in the treatment of Acquired Von Willebrand Syndrome associated with IgM gammopathy. Haemophilia, 2018, 24, e22-e25.	1.0	7
34	SIPPET: insights into factor VIII immunogenicity. Journal of Thrombosis and Haemostasis, 2018, 16, 36-38.	1.9	1
35	von Willebrand factor clearance â€“ biological mechanisms and clinical significance. British Journal of Haematology, 2018, 183, 185-195.	1.2	51
36	Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances, 2018, 2, 1784-1791.	2.5	79

#	Article	IF	Citations
37	Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma. Blood, 2018, 132, 1223-1223.	0.6	1
38	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood, 2017, 130, 2344-2353.	0.6	98
39	PT-VWD posing diagnostic and therapeutic challenges â€“ small case series. Platelets, 2017, 28, 484-490.	1.1	9
40	Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. Journal of Thrombosis and Haemostasis, 2016, 14, 1200-1205.	1.9	27
41	X-linked moyamoya syndrome associated with severe haemophilia A. Haemophilia, 2016, 22, e51-e54.	1.0	12
42	New treatment approaches to von Willebrand disease. Hematology American Society of Hematology Education Program, 2016, 2016, 683-689.	0.9	27
43	Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 855-863.	1.1	23
44	Recurrent lower limb venous thrombosis associated with a congenitally absent infrarenal inferior vena cava. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 57-57.	0.2	1
45	Novel Insights into the Clinical Phenotype and Pathophysiology Underlying Low VWF Levels: The Low Von Willebrand Factor in Ireland Cohort (LoVIC) Study. Blood, 2016, 128, 873-873.	0.6	2
46	Age-related factor IX correction in symptomatic female carriers with haemophilia B Leyden. Haemophilia, 2015, 21, e498-e500.	1.0	5
47	von Willebrand factor arginine 1205 substitution results in accelerated macrophageâ€dependent clearance in vivo. Journal of Thrombosis and Haemostasis, 2015, 13, 821-826.	1.9	28
48	Longitudinal bleeding assessment in von willebrand disease utilising an interim bleeding score. Journal of Thrombosis and Haemostasis, 0, , .	1.9	5